Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$477.41 USD

477.41
2,104,200

+15.02 (3.25%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $477.56 +0.15 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Zacks Equity Research

Integer Holdings (ITGR) Buys Oscor, Boosts Global Footprint

by Zacks Equity Research

Integer Holdings' (ITGR) acquisition of Oscor is likely to bolster its already solid global presence.

Zacks Equity Research

Is Invesco Dynamic Large Cap Growth ETF (PWB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWB

Zacks Equity Research

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Zacks Equity Research

HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.

Zacks Equity Research

Here's Why You Should Retain Abiomed (ABMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.

Zacks Equity Research

BD's (BDX) Buyout of Venclose to Improve Patient Outcome

by Zacks Equity Research

BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.

Zacks Equity Research

Avanos Medical's (AVNS) App to Support Pain Management Process

by Zacks Equity Research

Avanos Medical's (AVNS) new solution to help healthcare providers with respect to patients' overall pain management process.

Zacks Equity Research

Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools

by Zacks Equity Research

Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.

Zacks Equity Research

3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.

Zacks Equity Research

Cooper Companies (COO) Q4 Earnings Lag Estimates, Margins Up

by Zacks Equity Research

Cooper Companies' (COO) fiscal fourth-quarter results reflect solid segmental and geographical performances.

Zacks Equity Research

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.

Zacks Equity Research

Is Thermo Fisher Scientific (TMO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Thermo Fisher Scientific (TMO) and West Pharmaceutical Services (WST) have performed compared to their sector so far this year.

Zacks Equity Research

Veeva Systems (VEEV) Q3 Earnings Beat Estimates, '22 View Up

by Zacks Equity Research

Veeva Systems' (VEEV) fiscal Q3 results reflect impressive performances by both its segments.

Zacks Equity Research

Here's Why You Should Retain Boston Scientific (BSX) for Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Bunge, Expeditors, Tractor Supply Co, Watsco and Thermo Fisher Scientific

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Bunge, Expeditors, Tractor Supply Co, Watsco and Thermo Fisher Scientific

Zacks Equity Research

Patterson Companies (PDCO) Beats on Q2 Earnings & Revenues

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal second-quarter 2022 results benefit from strength in the Animal Health segment.

Zacks Equity Research

Here's Why You Should Invest in NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR.

Zacks Equity Research

Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome

by Zacks Equity Research

Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.

Nalak Das headshot

Virus and Fed Dampen Investors' Morale: 5 Low-Beta Stock Picks

by Nalak Das

We have narrowed our search to five large-cap low-beta stocks that have provided higher returns than the market's benchmark the S&P 500 Index year to date. These are: TSCO, BG, EXPD, WSO and TMO.

Zacks Equity Research

DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients

by Zacks Equity Research

DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

Zacks Equity Research

OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing

by Zacks Equity Research

OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.

Zacks Equity Research

3 Reasons to Retain Integer Holdings (ITGR) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and its focus on growth strategies.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.